Sordo, L. et al., “Mortality Risk During and After Opioid Substitution Treatment: Systematic Review and Meta-Analysis of Cohort Studies,” BMJ 357, no. 14 (2017): j1550.Google Scholar

U.S. Department of Health and Human Services, Office of the Surgeon General, “Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health,” Rockville, MD, 2016.Google Scholar

Swenson, I., “Substance-Abuse Treatment and Mortality,” Journal of Public Economics 122 (Feb. 2015): 13–30.Google Scholar

Title V(B), 122 Stat. 3765, 3881-3893 (2008).Google Scholar

McGuire, T.G., “Achieving Mental Health Care Parity Might Require Changes in Payments and Competition,” Health Affairs 35, no. 6 (2016): 1029–1035.Google Scholar

Bergquist, S.L., “Intervening on the Data to Improve the Performance of Health Plan Payment Methods,” NBER Working Paper No. 24491 (April 2018); A. Shrestha et al., “Mental Health Risk Adjustment with Clinical Categories and Machine Learning,” Health Services Research 15 (2017); E. Montz et al., “Risk-Adjustment Simulation: Plans May Have Incentives To Distort Mental Health and Substance Use Coverage,” Health Affairs 35, No. 6 (2016): 1022-1028; T.J. Layton, T.G. McGuire, and R.C. van Kleef, “Deriving Risk Adjustment Payment Weights to Maximize Efficiency of Health Insurance Markets,” at 4 (NBER 2016); R.C. van Kleef et al., “Improving Risk Equalization with Constrained Regression,” NBER Working Paper No. 21570 (Sept. 2015): 1-18.Google Scholar

McGuire, supra note 5.Google Scholar

Id. at 1031-1032.Google Scholar

Center On Addiction, “New Campaign Announced to Achieve Effective Parity Enforcement in 10 States,” November 14, 2017, available at <https://www.centeronaddiction.org/newsroom/press-releases/new-campaign-announced-achieve-effective-parity-enforcement-10-states> (last visited November 6, 2018).+(last+visited+November+6,+2018).>Google Scholar

Natalie V. v. Health Care Serv. Corp., No. 15 C09174, 2016 U.S. Dist. LEXIS 123783, at *10 (N.D. Ill. Sep. 13, 2016).Google Scholar

42 U.S.C. § 18022.Google Scholar

E.g., S. 1156(a), 2017-2018 Reg. Sess., (NY 2017) (proposed legislation amending parity law in New York to provide for more effective enforcement structure advocated by Parity @ 10 campaign). Weber, E. et. al., “Parity Tracking Project: Making Parity a Reality, Addition Solutions Campaign (2017),” available at <https://lac.org/wp-content/uploads/2017/06/ES_ParityTrackingReport_ASC.pdf> (last visited July 12, 2018).+(last+visited+July+12,+2018).>Google Scholar

McGuire, supra note 5.Google Scholar

Baker, T., “Health Insurance, Risk, and Responsibility after the Patient Protection and Affordable Care Act,” University of Pennsylvania Law Review 159, no. 6 (2011): 1577–1622; E. Montz et al., supra note 6.Google Scholar

CMS, Announcement of CY 2017 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter (April 4, 2016).Google Scholar

Hall, M.A., “Risk Adjustment Under the Affordable Care Act: Issues and Options,” Kansas Journal of Law & Public Policy 20 (2011): 222–236, at 224-225.Google Scholar

McGuire, supra note 5.Google Scholar

CMS, March 31, 2016 HHS-Operated Risk Adjustment Methodology Meeting Discussion Paper (March 24, 2016): 31.Google Scholar

See HHS Notice of Benefit and Payment Parameters for 2019, 83 Fed. Reg. 16930, 16942-16943 (April 17, 2018); 2019 ACA Notice of Benefit and Payment Parameters (acknowledging but rejecting requests to include prescription drug data regarding mental health and SUD; requests cited Montz et al., supra note 6); CMS, Announcement of CY 2019 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter 43-44 (Apr. 2, 2018) (announcing new diagnoses such as “Drug Abuse, Uncomplicated, Except Cannabis”). The 21st Century Cures Act directed the Secretary to consider adding additional mental illness and SUD diagnoses to the Part C risk adjustment model. 42 U.S.C. 1395w–23(a)(1)(I)(i)(I).Google Scholar

42 U.S.C. §§ 1395w-23 (Part C), 1395w-115 (Part D), 18063 (ACA).Google Scholar

See generally CMS, Announcements and Documents, available at <https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Announcements-and-Documents.html> (last visited November 6, 2018) (collecting annual Medicare Advantage and Part D actions); CMS, Regulations and Guidance, available at <https://www.cms.gov/CCIIO/Resources/Regulations-and-Guidance/index.html#%20Affordable%20Care%20Act> (last visited November 6, 2018) (collecting, under “premium stabilization programs,” annual notices for ACA).+(last+visited+November+6,+2018)+(collecting+annual+Medicare+Advantage+and+Part+D+actions);+CMS,+Regulations+and+Guidance,+available+at++(last+visited+November+6,+2018)+(collecting,+under+“premium+stabilization+programs,”+annual+notices+for+ACA).>Google Scholar

Pope, G.C. et al., “Evaluation of the CMS-HCC Risk Adjustment Model: Final Report,” RTI Project Number 0209853.006 (March 2011): 18–19.Google Scholar

Cf. 42 U.S.C. 1395w-23(a)(1)(C)(iii) (illness-specific risk adjustment for new enrollees who are “special needs individuals with chronic health conditions”).Google Scholar

Montz, supra note 6. A “bug” of using prescription drug data is that doing so might encourage prescriptions, but this may be a feature when it comes to under-treated illnesses.Google Scholar

Van Kleef et al., supra note 6 (constrained regression); Shrestha et al., supra note 6 (machine learning).Google Scholar

42 U.S.C. § 1395w-23(a)(1)(C)(i).Google Scholar

42 U.S.C. § 1395w-115(c)(1).Google Scholar

42 U.S.C. § 18063.Google Scholar

42 U.S.C. 1395w-23(a)(1)(C)(iii)(III).Google Scholar

Pope et al., supra note 22.Google Scholar

Layton, supra note 6.Google Scholar

Bergquist et al., supra note 6 at 23-24 (discussing comparative strengths and weaknesses of this and other approaches in light of upcoding, accuracy, and other considerations).Google Scholar

Bergquist et al., supra note 6 at 14, 19.Google Scholar

42 U.S.C. § 1395w-23(a)(1)(C)(ii)(IV) (Part C diagnostic, cost, and use data); 42 U.S.C. § 1395w-115(c)(1)(A) (“variation in costs for basic prescription drug coverage”).Google Scholar

42 U.S.C. § 1315a.Google Scholar

42 U.S.C. § 18063.Google Scholar

Id.Google Scholar

42 U.S.C. § 1395w-23.Google Scholar

Cf. Minuteman Health Inc. v. Burwell, 191 F. Supp. 3d 174, 198-99 (D. Ma. 2018) (recognizing agency discretion to consider values other than actuarial risk); New Mexico Health Connections v. HHS, 2018 WL 1136901, *28 (D. N.M. 2018) (same).Google Scholar